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In order to study the roles of individual BAs and due to limited blood sample volumes available from experimental animals, improved 15 
methods for the simultaneous quantification of multiple BAs are needed. We developed and validated an ultra-performance liquid 
chromatography tandem mass spectrometry (UPLC-MS/MS) method for the quantification of 24 BAs, including 11 unconjugated, 6 
glycine-conjugated and 7 taurine-conjugated BAs, in 50 µL of rat serum or plasma. The UPLC-MS/MS method, operated in negative and 
positive ion mode, allows quantification of BAs using multiple-reaction monitoring (MRM), with specific fragmentation of BAs. The 
method showed acceptable intra- and inter-day accuracy, precision, extraction recovery and high sensitivity, with lower limit of 20 
quantification (LLOQ) in the pM range for several taurine-conjugated BAs. We applied the established method to investigate potential 
time-dependent changes of BAs in plasma from sham-operated and uninephrectomized male Sprague-Dawley rats. The levels of several 
primary and secondary BAs were transiently elevated one week after uninephrectomy, followed by normalization thereafter. In contrast, 
several conjugated BAs were slightly increased after the second week post-surgery. The established UPLC-MS/MS method, employing 
specific fragmentation of free and conjugated BAs by MRM, allows the simultaneous quantification of multiple BAs in 50 µL serum or 25 
plasma samples, and can be used to assess BA profiles in patho-physiological situations.  
 
A Introduction 
The importance of bile acids (BAs) as end products of cholesterol 
catabolism and as emulsifiers for the absorption of dietary lipids 30 
and lipid soluble vitamins (A and D) has long been known 1-3. 
More recently, their ability to activate nuclear receptors such as 
the farnesoid-X-receptor (FXR-α), pregnane-X-receptor (PXR), 
constitutive androstane receptor (CAR), vitamin D receptor 
(VDR) and G-protein coupled bile acid receptor (TGR5), as well 35 
as their role in liver regeneration have been identified 4-7. 
Through the modulation of the activities of these various 
receptors, BAs regulate their own homeostasis as well as that of 
lipids and glucose, thereby controlling energy metabolism and 
thus opening new opportunities for therapeutic interventions to 40 
combat metabolic diseases 3, 8, 9. Besides, BAs are involved in the 
solubilization and excretion of xenobiotics and are thus of 
toxicological relevance. Therefore, establishing novel, highly 
sensitive and accurate methods enabling the simultaneous 
quantification of a larger number of BAs in biofluids from normal 45 
and pathological conditions is expected to broaden our 
understanding of their functions. 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) 
has been considered the gold standard for quantification of BAs 
in biological fluids and tissues, due to several advantages over 50 
traditional techniques such as gas chromatography (GC)-MS, 
including ease of sample preparation and no need for hydrolysis 
of conjugated BAs or complex derivatization reactions 10. 
However, despite the technological advance in MS to increase 
sensitivity, several problems still remain to be overcome such as 55 
requirement of large sample volumes depending on the analyte to 
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be quantified 11, need for derivatization depending on the 
availability of sample amount 12, interference with contaminating 
endogenous BAs in biological matrices 11, and limited specificity 
when using selective ion monitoring (SIM) for quantification 10. 
Although there is a consensus in the literature regarding the use 5 
of multiple reaction monitoring (MRM) for the quantification of 
taurine- and glycine-conjugated BAs, MRM has not yet been 
widely used for quantification of unconjugated BAs 11, 13-25. In the 
present study, we applied specific fragmentation using MRM for 
both conjugated and unconjugated BAs in order to increase the 10 
specificity of detection and sensitivity for quantification of BAs 
in complex biological matrices such as serum and plasma. 
Primary BAs are synthesized and conjugated in hepatocytes, 
followed by excretion into bile and the intestinal tract. Gut 
microorganisms generate secondary BAs by deconjugation and 15 
dehydroxylation. Upon reuptake by intestinal transporters, BAs 
are reconjugated in the liver to complete the enterohepatic cycle. 
BAs can also be filtered in the kidney through the glomerulus, 
followed by urinary excretion. Most BAs undergo reuptake by 
renal tubular transporters and, under normal conditions, the 20 
amount of excreted BAs is low. However, impaired hepatorenal 
function can lead to increased urinary BA excretion.  
The kidney has a key role in the control of whole body 
homeostasis, including electrolyte balance and blood pressure, 
production and  utilization of systemic glucose, degradation of 25 
hormones and excretion of waste metabolites 26. Recent 
observations unravelled the importance of the kidney in the 
regulation of lipid metabolism, fat distribution and adipocyte 
differentiation 27. In rats reduced renal function upon 
uninephrectomy has been linked with several aspects of the 30 
metabolic syndrome such as lipodystrophy of subcutaneous and 
visceral adipose depots, with lipid depletion, adipocyte 
dedifferentiation, lipid peroxidation, hypercholesterolemia and 
hypertriglyceridemia 28. Similarly, nondiabetic patients on 
hemodialysis manifested fat redistribution with increasing 35 
visceral fat and altered serum lipid profiles 29. These findings 
indicate that reduced renal function can cause disturbances of 
lipid homeostasis. Due to the close association between BA 
signaling and metabolic homeostasis 30-33 and the observed 
impact of reduced kidney function on lipid homeostasis, we 40 
investigated the impact of uninephrectomy in rats on plasma BA 
profiles by applying the validated UPLC-MS/MS method.  
 
A Materials and Methods 
B Ethics statement 45 
 
The animal experimental protocol was approved by the Ethical 
Committee of the Veterinary Office of Fribourg, Switzerland. 
B Chemicals and reagents 
Cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic 50 
acid (DCA), lithocholic acid (LCA), ursodeoxycholic acid 
(UDCA), glyco-deoxycholic acid (G-DCA), glyco-
chenodeoxycholic acid (G-CDCA), tauro-chenodeoxycholic acid 
(T-CDCA), [2,2,4,4-2H4]-CA (98% isotopic purity), [2,2,4,4-
2H4]-CDCA (>98% isotopic purity) and [2,2,4,4-2H4]-LCA 55 
(98% isotopic purity) were purchased from Sigma-Aldrich (St. 
Louis, MO). 7-oxodeoxycholic acid (7-oxoDCA), 7-
oxolithocholic acid (7-oxoLCA), hydeoxycholic acid (HDCA), α-
muricholic acid (α-MCA), β-muricholic acid (β-MCA), ω-
muricholic acid (ω-MCA), glyco-lithocholic acid (G-UDCA), 60 
tauro-lithocholic acid (T-LCA), tauro-α-muricholic acid (T-α-
MCA), tauro-β-muricholic acid (T-β-MCA) and [2,2,4,4-2H4]-
DCA (98% isotopic purity) were obtained from Steraloids 
(Newport, RI). Glyco-cholic acid (G-CA), tauro-cholic acid (T-
CA), tauro-deoxycholic acid (T-DCA) and tauro-ursodeoxycholic 65 
acid (T-UDCA) were purchased from Calbiochem (Läufelfingen, 
Switzerland), and [2,2,4,4-2H4]-UDCA (>98% isotopic purity), 
[2,2,4,4-2H4]-G-CA(>98% isotopic purity), [2,2,4,4-2H4]-G-
CDCA (>98% isotopic purity) and [2,2,4,4-2H4]-G-UDCA 
(>98% isotopic purity) from C/D/N Isotopes Inc. (Pointe-Claire, 70 
Canada). The conjugated bile acids tauro-7-oxoLCA (T-7-
oxoLCA) and glyco-7-oxoLCA (G-7-oxoLCA) were a gift from 
Dr. Alan F. Hofmann (University of California at San Diego, San 
Diego, CA, USA). All other chemicals were from Fluka AG 
(Buchs, Switzerland) of the highest grade available. 75 
 
B Preparation of stock solutions, calibrators and quality 
control (QC) samples 
 
Stock solutions were prepared in methanol for each standard and 80 
deuterium-labeled internal standards (IS) at a concentration of 10 
mM. Thereafter, working solutions containing standards and 
deuterium-labeled IS (100 µM each) were prepared. All stock 
solutions of standards and deuterium-labeled IS were stored at -
20ºC. Unspiked charcoal-treated rat serum represented the zero 85 
calibration point. Calibration curves were prepared by serial 
dilution of the working solutions of standards in charcoal-treated 
pooled male rat serum (Dunn Labortechnik GmbH, Asbach, 
Germany). For that purpose, 100 mg/mL of activated charcoal 
was stirred overnight at 4ºC, and centrifuged thereafter for 20 min 90 
at 13,000 × g to remove endogenous BAs. Following three 
centrifugation cycles, the supernatant was filtered through a 0.20 
µm membrane and stored in aliquots at -20ºC until further use. 
The absence of remaining endogenous BAs from the matrix was 
verified by UPLC-MS/MS.  95 
 
B Animal preparation and experimental protocol 
 
Male Sprague Dawley rats (Elevage Janvier, France) of ~5 weeks 
of age were caged singly in a temperature-controlled room (22 ± 100 
1°C) with a 12-h light/dark cycle. After one week of acclimation, 
the rats (eight animals per group) underwent surgery under 
general anesthesia with ketamine/xylazine (150 mg/kg and 2 
mg/kg, respectively) and sterile conditions for uninephrectomy or 
sham-surgery.  Briefly, an incision was made on the left flank to 105 
access kidney retroperitoneally. In half of the rats, renal blood 
vessels and the urethra were ligated with a surgical thread, the 
connection to the kidney was cut and the kidney removed. 
Tissues were sutured and the wound was closed with metal clips. 
In sham-operated rats, the surgery was identical except that the 110 
kidney was left intact in place. For the whole experiment, rats 
were fed an isocaloric diet 90 kcal/day (low fat diet Nr 2125 from 
Kliba, Kaiseraugst, Switzerland). Eight rats per group were 
sacrificed by decapitation 1 week, 2 weeks and 4 weeks after 
surgery, and blood was collected from the neck immediately after 115 
decapitation in EDTA tubes under ice and cold-centrifuged. The 
plasma was separated and stored at -20°C for later analysis.  
 
B Sample preparation 
 120 
Plasma samples (total volume of 50 µL) and calibrators were 
subjected to protein precipitation by adding 500 µL of ice-cold 
acetonitrile containing deuterium-labeled internal standards (IS), 
at a final concentration of 100 nM each of CA-d4, CDCA-d4, 
DCA-d4, UDCA-d4, G-CA-d4, G-CDCA-d4 and G-UDCA-d4. 125 
The final concentration of LCA-d4 was adjusted to 1000 nM due 
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to its low ionization efficiency. The concentrations of IS used are 
similar to those used by other investigators and did not interfere 
with the concentrations of endogenous BAs found in samples 23. 
Extraction was performed for 30 min at 4ºC with continuous 
shaking. Samples were centrifuged at 14,000 × g for 15 min at 5 
4ºC, and the supernatants transferred to new tubes, followed by 
evaporation and reconstitution in 50 µL of methanol/water of 
50/50 (v/v). The injection volume was 5 µL. 
 
B Separation, ionization and detection conditions 10 
 
The UPLC-MS/MS consisted of an Agilent 1290 UPLC coupled 
to an Agilent 6490 triple quadrupole mass spectrometer equipped 
with an electrospray ionization (ESI) source (Agilent 
Technologies, Basel, Switzerland). Separation of analytes was 15 
achieved using reversed-phase column (ACQUITY UPLC BEH 
C18, 1.7 µm, 2.1×150 mm, Waters, Wexford, Ireland) heated to 
65ºC. Data acquisition and analysis was performed using Mass 
Hunter software (Agilent Technologies).  
The mobile phase consisted of water-acetonitrile-formic acid (A) 20 
(95/5/0.1; v/v/v) and (B) (5/95/0.1; v/v/v). The eluent gradients 
were set from 25% - 35% of B during 0 - 8 min, 35% -70% eluent 
B during 8 - 18 min and 95% of B at 18.1 min onwards. The run 
was stopped at 20 min, followed by re-equilibration of the 
column. The flow rate was set to 0.75 mL/min. Ionization was 25 
performed using an ESI source operated in the positive and 
negative ion modes. Fragmentation was tuned for each compound 
using Optimizer software (Agilent Technologies). Optimized 
conditions are shown in Table 1. The source parameters were set 
to gas temperature 350°C, gas flow 15 L/min, nebulizer pressure 30 
20 psi, sheath gas temperature 250ºC, sheath gas flow 11 L/min, 
capillary voltage 3000 V (positive and negative), nozzle voltage 
2000 V and cell accelerator voltage 5 V.  
 
B Method validation 35 
  
Method validation was performed according to the FDA 
guidelines for Bioanalytical Method Validation 34. The linearity 
of each BA calibration curve was determined by analyzing 
charcoal treated rat serum prepared to contain standards at the 40 
concentration range of 0.12 nM, 0.98 nM, 7.8 nM, 62.5 nM, 500 
nM and 4 µM. Calibration curve linearity was evaluated by 
assessing the correlation coefficient (R2) of three freshly prepared 
calibration curves. Standard curves were constructed by least-
squares linear regression analysis using peak area ratio of a given 45 
BA over its reference IS against the nominal concentration of the 
calibrator. Quantification of samples was performed identically. 
Due to unavailability of reference IS, 7-oxoDCA, HDCA, 7-
oxoLCA, α-MCA, β-MCA, ω-MCA, G-DCA, G-LCA, G-7-
oxoLCA, T-CA, T-CDCA, T-DCA, T-LCA, T-7-oxoLCA, T-β-50 
MCA and T-UDCA were semi-quantified by referring to a 
surrogate deuterium-labeled IS  (Table 1).  
Values of the lower limit of quantification (LLOQ) were 
calculated by assessing the signal to noise ratio (SNR) (baseline 
noise determined on an interval before and after the peak of 55 
interest and using the peak height as signal definition). Five 
replicates were extracted and analyzed for each concentration. A 
signal equal or higher than ten times that of the baseline was 
considered the LLOQ, with accuracy between 80 and 120% of 
the true value and coefficient of variation (CV) of 15%. Due to 60 
the persistence of trace amounts of G-CA, G-CDCA and G-DCA 
after charcoal treatment, their LLOQs were determined as being 
the lowest concentration at which these analytes could be 
quantified with sufficient precision (CV of 15%) and accuracy 
(between 85% and 115%). 65 
In order to assess intra- and inter-day precision and accuracy, five 
replicates of five different quality control samples (QC) with 
concentrations ranging from 0.002 µM to 2 µM were extracted 
and quantified using freshly prepared calibrators in charcoal 
treated rat serum. Replicates of each QC sample were analyzed in 70 
a given day in order to determine intra-day accuracy and 
precision as well as over a period of three days (inter-day) using 
freshly prepared calibration curves.  
Recovery experiments were performed using untreated and 
charcoal-treated serum samples in order to mimic extraction 75 
conditions similar to those of real samples and to access the 
impact of matrix components on extraction recoveries. In order to 
assess extraction recovery, twelve untreated and charcoal-treated 
serum samples were taken for each of the concentration levels 
(2000 nM, 200 nM and 20 nM). From these twelve samples, six 80 
were spiked with the appropriate amount of standard stock 
solution and IS prior to extraction, and the remaining six samples 
were extracted as blanks and reconstituted with the same amount 
of standard stock solution and IS after extraction. Six additional 
unspiked serum samples were extracted in order to determine 85 
endogenous concentrations of BAs. Thereafter, samples were 
evaporated, reconstituted and injected. Correction of the spiked 
serum samples was performed by subtracting the endogenous 
amounts of the respective BAs. Recovery results were obtained 
by expressing the average of the mean peak area of samples 90 
spiked prior to extraction as a percentage of that of samples 
spiked after extraction. 
Matrix effects were assessed by using untreated pooled rat serum 
in order to mimic chemical conditions of those of real samples.  
For that purpose, six samples were spiked with defined amounts 95 
of standard stock solutions (2000 nM, 200 nM and 20 nM) and IS 
after extraction. Six additional unspiked serum samples were 
extracted in order to determined endogenous concentration of 
BAs. Thereafter, all samples were evaporated and reconstituted in 
mobile phase. Correction of the spiked serum samples was 100 
performed by subtracting the endogenous amounts of the 
respective BAs, and matrix effects were calculated by expressing 
the peak area of spiked serum samples after extraction as a 
percentage of the peak area of that of net solutions containing 
only the pure standard in methanol. 105 
 
 
Figure 1.Structure of BAs. 
 
B Statistical analysis 110 
Data are presented as mean ± SD. Statistical significance was 
assessed by Student´s t-test.  
Page 3 of 14 Analytical Methods
A
n
al
yt
ic
al
 
M
et
ho
ds
 
A
cc
ep
te
d 
M
an
u
sc
rip
t
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  4 
 . 
 
 
Figure 2. Representative chromatogram of bile acids extracted from plasma sample and charcoal-treated rat serum spiked with 24 bile 5 
acids standard 
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A Results and Discussion 
In the present study, a sensitive and specific UPLC-MS/MS 
method for the quantification of 24 BAs, including 11 
unconjugated, 6 glycine- and 6 taurine-conjugated BAs was 
developed. Additionally, T-α-MCA was included in the analytical 5 
method after validation. The method was validated according to 
the Food and Drug Administration (FDA) guidelines 34, using 50 
µL of rat serum. In the validation procedure we included the 
following parameters: linearity of calibration curves, inter- and 
intra-day accuracy and precision, extraction recoveries and matrix 10 
effects. Following validation, the method was applied to 
determine BAs profiles in plasma of sham-operated and 
uninephrectomized male Sprague-Dawley rats.  
 
 15 
B Chromatography and ionization conditions 
 
Due to the fact that it is impossible to differentiate isobaric BA 
species by MS, a prior chromatographic step is needed (see 
Figure 1 for structures). Our chromatography conditions allowed 20 
the separation of the 24 BAs in a 20 min run using a reversed-
phase column heated to 65ºC (Figure 2). T-α-MCA and T-β-
MCA peaks were resolved with a resolution of approximately 1.0 
(Figure 2, insert). In order to gain sensitivity, the MS program 
was divided in segments in which defined transitions were 25 
monitored according to the retention time of the metabolites. An 
electrospray ionization (ESI) source operating in the negative ion 
mode was used for glycine-conjugated BAs and in the positive 
ion mode for unconjugated and taurine-conjugated BAs (Table 
1). Most studies so far reported the use of negative ion mode for 30 
the quantification of BAs in biological  matrices 11, 13, 15-25, 35-37. In 
spite of this, we found that ESI-positive ion mode provided 
higher ionization efficiency for unconjugated and taurine-
conjugated BAs, regardless of whether formic acid or ammonium 
formate was used as ionizing agent. Moreover, we obtained more 35 
stable and abundant fragments for MRM transitions of 
unconjugated BAs in positive but not in negative ion mode. 
Superior signal-to-noise ratios (SNR) and LOD values (SNR~3) 
have been obtained with positive ion mode. LCA, for example, 
could not be quantified in negative ion mode using transitions 40 
reported in the literature (Figure S1 and S2) 23. This may be 
explained by the solvent system employed in the present study. 
Supporting this idea, Qiao et. al. reported more efficient 
ionization of DCA in ESI-negative mode using a solvent system 
consisting of water-methanol compared with acetonitrile, while 45 
maintaining reasonable signal intensity in positive ion mode 38. 
Controversially, García-Canãveras et al. used acetonitrile as a 
solvent and negative ion mode for quantification of DCA and 
LCA, with LLOQ of 5 and 10 nM, respectively. The discrepancy 
between results obtained in positive and negative ion mode may 50 
be dependent, at least in part, on the different instruments used. 
 
   
B Fragmentation of BAs 
 55 
To achieve higher specificity and sensitivity in the quantitative 
analysis of BAs in biological samples, we aimed at defining 
MRM transitions for each metabolite, including unconjugated 
BAs (Table 1). Several earlier studies reported stable fragments 
for conjugated BAs; however, identical precursors and product 60 
ions were employed for the quantification of free BAs 11, 13-23. 
This approach is called selective ion monitoring (SIM) and, 
although useful, it has limited specificity 10. There are only few 
studies on the fragmentation of unconjugated BAs 24, 25, and it is 
important to identify and validate novel fragments that may 65 
enhance sensitivity and specificity for the quantification of BAs 
in biological matrices. Fragmentation of BAs was defined by 
direct injection of each individual standard into the MS, and 
identification of the most abundant fragments by was performed 
using Optimizer software (Agilent technologies). Glycine- and 70 
taurine-conjugated BAs were efficiently fragmented, yielding the 
product ions m/z 74 and 126, respectively. This fragmentation 
pattern is derived from the elimination of glycine and taurine, 
respectively 38. The unconjugated BAs 7-oxoLCA, 7-oxoDCA, α-
MCA, β-MCA, ω-MCA and CA yielded product ions by the 75 
consecutive neutral loss of water molecules, so-called dehydrated 
BAs. HDCA, UDCA, CDCA and DCA were fragmented to 
generate the ion m/z 95.1, whereas LCA was monitored with m/z 
135.1. Deuteurium-labeled IS yielded fragmentation patterns 
similar to those of their corresponding non-deuterated forms 80 
(Table 1). In a recent study Qiao, et. al. characterized the 
fragmentation behavior of BAs 38. They found similar 
fragmentation patterns for taurine- and glycine-conjugated BAs 
and also observed the neutral loss of water for CA and the ion 
m/z 135.1 for LCA. However, the ion m/z 95.1 for CDCA, 85 
UDCA, HDCA and DCA detected in the present study has not yet 
been described or validated 38. The differences in fragmentation 
behavior and peak abundances are probably due to limitations in 
low mass measurements by the different instruments used. 
Although Qiao et al. reported on the fragmentation patterns of 90 
several BAs, they did not investigate the applicability, 
reproducibly and robustness of BA fragments for MRM 
quantification. Here, we report the identification and applicability 
of novel fragments for the quantification of free BAs using 
UPLC-MS/MS. The use of fragmentation conditions not only for 95 
conjugated, but also for unconjugated BAs is expected to enhance 
specificity and sensitivity of measurements.  
 
B Inter- and intra-day accuracy, precision, linearity and 
lower limits of quantification (LLOQ) 100 
 
Overall accuracy and precision were appropriate for all 
measurements (Table 2). Intra- and inter-day accuracy ranged 
from 85% to 115%. Intra- and interday precision measured as 
coefficient of variation (CV) (%) ranged from 1.1% to 15.0% 105 
(Table 2). Accuracy and precision were also evaluated for 
selected bile acids (TCA, GCDCA, GUDCA, DCA, CA, LCA, 
CDCA and α-MCA) in a fortification assay by adding 3 
increasing concentrations (+25%, +50% and +100% of 
endogenous) to samples, and acceptable accuracy and precision 110 
intervals were obtained (data not shown). Linearity of calibration 
curves was acceptable with a correlation coefficient after linear 
regression of ≥ 0.99 (Table 3). The LLOQ was defined as the 
lowest concentration of a given analyte with a signal-to-noise 
ratio (SNR) ≥ 10. The LLOQs for BAs obtained in the present 115 
study ranged from 200 pM to 25 nM. Surprisingly, T-CDCA, T-
DCA, T-LCA, T-β-MCA and T-UDCA reached LLOQs at the 
pM range and are remarkably lower than those of previous 
studies (Table 3) 18, 23. This can be explained by employing MRM 
and using specific fragments for quantification of BAs, thereby 120 
reducing the SNR in the second mass filter and improving 
sensitivity. Recently, García-Cañaveras et al. reported 
comparable LLOQs for a number of unconjugated BAs in 25 µL 
of sample volume using SIM operated in negative ion mode, 
differences that are likely to be caused by different sensitivities of 125 
the instruments used 23. Nevertheless, MRM is generally accepted 
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as the superior approach for the specific determination of 
chemicals, and therefore its usage is likely to improve the quality 
of data generated. 
  
B Extraction recovery and matrix effects 5 
 
Since it was reported that solid phase extraction (SPE) is not 
optimal for BAs extraction owing to low recovery for some 
analytes 23, and to avoid excessive sample handling, a single 
extraction step using acetonitrile was performed in the present 10 
method. The deuterium-labeled IS UDCA-d4, CDCA-d4, LCA-
d4, G-UDCA-d4, G-CA-d4, CA-d4 and DCA-d4 were included 
to minimize possible bias during extraction. 
Low extraction recoveries were observed for a few BAs (HDCA, 
G-DCA, G-LCA and G-UDCA), in contrast to a previous study 15 
using similar extraction procedure 14. A possible explanation for 
these discrepancies may be the presence of matrix components 
interfering with the extraction of the aforementioned BAs, 
because identical experiments using charcoal-treated instead of 
untreated rat serum provided superior extraction recoveries 20 
(Table S1). Overall, extraction recoveries using acetonitrile were 
reproducible across the concentration studied and ranged from 
33% to 110% in untreated serum and from 70% to 88% in 
charcoal-treated serum.   According to the FDA guidelines for 
validation of analytical methods, the recovery of a given analyte 25 
does not need to be 100%, but the amount of recovery must be 
consistent, precise and reproducible 34. Due to the fact that 
HDCA extraction recovery was discrepant between untreated and 
charcoal-treated samples, its value may not reflect the absolute 
concentration. Regarding matrix effects, the ionization of BAs 30 
studied was not affected by the matrix components at the three 
concentrations studied (Table 4). Overall, our findings are in line 
with that of other investigators 18. 
 
B Profiling of circulating BAs in sham-operated and 35 
uninephrectomized rats 
 
We hypothesized that reduced renal function might affect BA 
homeostasis due to reduced filtration capacity and/or proximal 
tubular reuptake. Therefore, we applied the established UPLC-40 
MS/MS method to determine BA profiles in sham-operated and 
uninephrectomized male Sprague-Dawley rats following one, two 
and four weeks after the surgical intervention (Table 5). A 2-fold 
increase in circulating total primary BAs was observed one week 
after uninephrectomy, which was fully reversed after the second 45 
week. The two most abundant primary BAs, CA and CDCA, 
were increased by 2.3- and 2.2-fold at one week post-surgery. 
The amount of total secondary BAs was also slightly elevated one 
week after uninephrectomy, followed by reversal to normal levels 
at the second week. In contrast to primary BAs, total taurine-50 
conjugated BAs remained unchanged at one week post-surgery, 
but they were increased by 40% after the second week and tended 
to be higher by 20% after the fourth week, suggesting a delayed 
response. Thus, the established method allowed the detection of 
transient changes in the levels of circulating BAs following 55 
uninephrectomy in rats. 
 
Conclusions 
We established a method for the quantification of BAs in serum 
and plasma by employing specific fragmentation of BAs, which 60 
has demonstrated to be robust, reproducible and accurate, thus 
enhancing the specificity of the quantitative analysis of BAs in 
biological samples. We applied the method to study the impact of 
uninephrectomy in healthy rats on BA homeostasis and observed 
that impaired kidney function indeed alters BA homeostasis by 65 
transiently increasing their circulating concentrations. The 
mechanisms and physiological significance of these findings 
remain to be further investigated.  
. 
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Table 1 Precursor and product ions of BAs with optimized fragmentation parameters (collision energy) as well as corresponding  5 
deuterium-labeled internal standard used for quantitative analysis  
 
 
 
 10 
 
 
 
 
 15 
 
 
 
 
 20 
 
 
 
 
 25 
 
 
 
 
 30 
 
BA Precursor Ion (m/z) Product ion (m/z) Collision energy (V) Polarity Internal Standard 
CA 373.3 355.2 48 Positive CA-d4 
CDCA 357.2 95.1 40 Positive CDCA-d4 
DCA 357.2 95.1 40 Positive DCA-d4 
7-oxoDCA 371.3 353.2 8 Positive DCA-d4 
HDCA 357.2 95.1 40 Positive UDCA-d4 
LCA 359.3 135.1 24 Positive LCA-d4 
7-oxoLCA 373.3 355.2 8 Positive UDCA-d4 
α-MCA 373.3 355.2 8 Positive UDCA-d4 
β-MCA 373.3 355.2 8 Positive UDCA-d4 
ω-MCA 373.3 355.2 8 Positive UDCA-d4 
UDCA 357.2 95.1 40 Positive UDCA-d4 
G-CA 464.2 74 37 Negative G-CA-d4 
G-CDCA 448.2 74 41 Negative G-CDCA-d4 
G-DCA 448.2 74 41 Negative G-CA-d4 
G-LCA 432.2 74 41 Negative G-UDCA-d4 
G-7-oxoLCA 446.2 74 37 Negative G-UDCA-d4 
G-UDCA 448.2 74 37 Negative G-UDCA-d4 
T-CA 480.3 126 24 Positive G-UDCA-d4 
T-CDCA 464.2 126 28 Positive G-CDCA-d4 
T-DCA 464.2 126 28 Positive DCA-d4 
T-LCA 466.2 126 28 Positive G-UDCA-d4 
T-7-oxoLCA 480.3 126 20 Positive G-UDCA-d4 
T-β-MCA 480.3 126 24 Positive G-DCA-d4 
T-UDCA 464.2 126 28 Positive G-UDCA-d4 
CA-d4 377.3 359.2 48 Positive - 
CDCA-d4 361.2 95.1 40 Positive - 
DCA-d4 361.3 95.1 40 Positive - 
LCA-d4 363.3 135.1 24 Positive - 
UDCA-d4 361.2 95.1 40 Positive - 
G-CA-d4 468.2 74 37 Negative - 
G-CDCA-d4 452.2 74 41 Negative - 
G-UDCA-d4 452.2 74 41 Negative - 
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Table 2.  Intra- and interday accuracy, precision of BA samples in serum 
 Intra-day 
 QC 2 nM QC 4 nM QC 100 nM QC 1000 nM QC 2000 nM 
 
CV 
(%) 
Accuracy 
(%) 
CV 
(%) 
Accuracy 
(%) 
CV 
(%) 
Accuracy 
(%) 
CV 
(%) 
Accuracy 
(%) CV (%) 
Accuracy 
(%) 
CA N.D. N.D. 6.4 100.0 2.5 111.1 1.5 93.0 
CDCA N.D. N.D. 2.1 88.0 2.2 99.3 1.9 102.7 
DCA N.D. N.D. 3.1 90.6 2.6 101.0 4.8 103.3 
7-oxoDCA N.D. N.D. 8.3 104.6 3.2 101.0 2.7 98.3 
HDCA N.D. N.D. 10.2 88.7 9.6 110.4 11.1 103.4 
LCA N.D. N.D. 6.2 94.2 3.8 95.0 6.4 98.5 
7-oxoLCA N.D. N.D. 5.1 109.9 3.2 102.4 6.3 102.7 
α-MCA N.D. N.D. 2.4 106.8 1.4 98.6 5.1 105.9 
β-MCA N.D. N.D. 6.5 103.7 4.3 108.0 2.4 101.7 
ω-MCA N.D. N.D. 5.9 95.8 2.2 108.7 9.5 98.6 
UDCA N.D. N.D. 8.6 96.3 3.5 106.0 3.9 102.3 
G-CA N.D. 12.9 95.2 2.9 87.5 4.2 105.8 4.5 96.5 
G-CDCA N.D. N.D. 2.4 91.2 2.3 104.2 1.8 90.6 
G-DCA 8.9 102.0 8.3 92.5 2.0 90.1 3.6 104.8 1.9 103.1 
G-LCA 10.4 111.1 7.4 102.6 2.7 90.1 6.4 100.2 1.9 99.5 
G-7-oxo-
LCA 5.4 113.8 3.3 88.5 1.5 86.8 3.2 108.0 3.6 94.6 
G-UDCA 7.7 106.8 11.7 102.6 3.2 95.4 6.8 112.5 1.7 94.7 
T-CA 9.3 96.2 8.8 105.3 4.7 94.3 1.9 101.9 3.2 96.3 
T-CDCA 10.6 88.4 8.2 91.7 3.8 93.8 2.6 105.0 3.2 104.5 
T-DCA 9.4 103.3 3.0 87.7 4.8 98.0 2.4 96.6 3.3 99.4 
T-LCA 8.6 108.2 12.6 101.0 4.2 99.4 4.6 100.0 4.0 96.7 
T-7-oxo-
LCA 14.8 92.6 6.4 97.6 3.4 92.9 4.2 93.5 3.2 98.6 
T-β-MCA 7.2 114.9 12.6 101.0 4.1 100.6 6.9 97.7 4.2 99.4 
T-UDCA 12.2 92.3 5.2 97.1 3.9 96.5 3.0 104.7 4.5 97.6 
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Table 2.  to be continued 
 
Inter-day 
 QC 2 nM QC 4 nM QC 100 nM QC 1000 nM QC 2000 nM 
 
CV 
(%) 
Accuracy 
(%) 
CV 
(%) 
Accuracy 
(%) 
CV 
(%) 
Accuracy 
(%) 
CV 
(%) 
Accuracy 
(%) 
CV 
(%) 
Accuracy 
(%) 
CA N.D. 5.5 96.8 5.2 99.4 4.4 97.0 3.8 93.8 
CDCA N.D. 6.0 93.4 2.2 97.4 1.9 95.1 3.8 97.1 
DCA N.D. 3.5 93.8 4.0 93.0 1.7 96.4 2.0 100.0 
7-
oxoDCA 
N.D. N.D. 5.1 106.6 1.9 100.2 1.2 104.0 
HDCA N.D. N.D. 4.6 92.0 3.0 94.8 3.7 96.1 
LCA N.D. N.D. 4.3 97.8 1.8 93.3 2.9 99.8 
7-oxoLCA N.D. N.D. 4.4 104.0 5.9 92.3 4.4 99.1 
α-MCA N.D. N.D. 3.8 99.4 3.5 92.4 5.4 98.1 
β-MCA N.D. N.D. 5.5 96.5 4.3 94.9 5.3 99.2 
ω-MCA N.D. N.D. 3.7 95.0 2.1 97.5 6.7 95.6 
UDCA N.D. N.D. 7.1 97.2 4.8 93.7 1.8 98.3 
G-CA N.D. 4.8 102.9 1.8 91.8 2.4 99.5 3.4 101.7 
G-CDCA N.D. N.D. 2.3 92.9 1.8 97.9 1.9 93.2 
G-DCA 12.3 90.1 7.2 96.0 2.4 93.3 2.3 98.7 4.9 101.4 
G-LCA 9.2 105.6 4.8 94.9 1.3 88.9 1.3 98.0 1.4 99.8 
G-7-oxo-
LCA 9.3 109.5 2.1 90.6 2.2 90.7 1.7 99.0 1.8 98.3 
G-UDCA 9.5 102.7 7.8 100.8 2.9 96.1 2.4 98.2 1.5 94.7 
T-CA 8.5 96.8 4.7 90.9 2.8 95.1 1.8 99.3 1.4 101.4 
T-CDCA 12.0 90.6 4.6 91.5 3.3 96.4 2.9 104.4 4.0 96.8 
T-DCA 14.2 102.1 2.5 86.8 2.1 96.2 5.0 99.9 1.1 104.2 
T-LCA 8.2 111.4 4.2 98.0 2.2 98.1 3.2 101.4 1.7 102.7 
T-7-oxo-
LCA 15.0 95.2 2.2 93.9 3.2 94.9 1.3 95.6 1.4 102.1 
T-β-MCA 11.7 109.5 5.5 92.4 2.1 95.1 4.3 99.9 2.8 104.3 
T-UDCA 12.3 95.4 2.5 87.2 3.1 94.3 3.7 104.7 3.1 105.5 
CV: Coefficient of variation. N.D.: Not determined owing to concentration below lower limit of quantitation. 
 
 5 
 
 
 10 
 
 
 
 
 15 
 
 
 
 
20 
Page 9 of 14 Analytical Methods
A
n
al
yt
ic
al
 
M
et
ho
ds
 
A
cc
ep
te
d 
M
an
u
sc
rip
t
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  10 
Table 3. Lower limit of quantification (LLOQ), retention time, linearity and recovery of BAs in rat serum 
Bile acids LLOQ (nM) SNR RT  (min) Linearity (R2) Calibration range (nM) Extraction recoveries (%) *
1 
20 nM 200 nM 2 µM 
CA 3 11 ± 4 9.3 0.9921 4000 – 0.98 78 ± 30 97 ± 14 70 ± 11 
CDCA 3 13 ± 4 12.3 0.9914 4000 – 0.98 76 ± 3 94 ± 12 83 ± 8 
DCA 3 10 ± 1 12.6 0.9985 4000 – 0.98 75 ± 12 86 ± 26 63 ± 7 
7-oxoDCA 25 11 ± 1 6.6 0.9955 4000 -7.8 78 ± 9 71 ± 16 73 ± 5 
HDCA 8 11 ± 2 9.6 0.9957 4000 -7.8 43 ± 8 33 ± 6 39 ± 9 
LCA 13 10 ± 2 15.5 0.9963 4000 – 7.8 95 ± 13 60 ± 4 68 ± 4 
7-oxoLCA 8 10 ± 2 10.5 0.9902 4000 -7.8 76 ± 22 68 ± 5 79 ± 3 
α-MCA 13 17 ± 3 6.3 0.9952 4000 -7.8 77 ± 6 64 ± 12 60 ± 9 
β-MCA 13 11 ± 2 6.7 0.9922 4000 -7.8 77 ± 11 66 ± 13 61 ± 8 
ω-MCA 13 16 ± 4 5.9 0.9954 4000 -7.8 76 ± 7 59 ± 7 54 ± 2 
UDCA 13 11 ± 2 9.3 0.9962 4000 -7.8 62 ± 15 68 ± 6 74 ± 4 
G-CA 3 N.A. *2 6.6 0.9926 4000 – 0.98 79 ± 13 71 ± 15 52 ± 12 
G-CDCA 6 N.A. *2 9.8 0.9970 4000 – 0.98 61 ± 6 58 ± 12 61 ± 8 
G-DCA 1 N.A. *2 10.4 0.9978 4000 – 0.98 57 ± 24 62 ± 3 58 ± 5 
G-LCA 1 17 ± 4 13.1 0.9936 4000 – 0.98 53 ± 1 56 ± 5 69 ± 4 
G-7-oxoLCA 1 18 ± 4 7.5 0.9910 4000 – 0.98 55 ± 1 64 ± 3 77 ± 6 
G-UDCA 1 12 ± 3 6.1 0.9951 4000 – 0.98 60 ± 12 60 ± 6 73 ± 5 
T-CA 1 14 ± 3 4.5 0.9955 4000 – 0.98 67 ± 18 92 ± 10 80 ± 4 
T-CDCA 0.2 10 ± 4 7.7 0.9900 4000 – 0.1221 65 ± 17 87 ± 9 89 ± 6 
T-DCA 0.2 10 ± 3 8.3 0.9947 4000 – 0.1221 78 ± 12 73 ± 6 83 ± 5 
T-LCA 0.4 12 ± 1 11.4 0.9910 4000 – 0.1221 62 ± 2 79 ± 5 93 ± 4 
T-7-oxoLCA 1 14 ± 3 5.2 0.9963 4000 – 0.98 60 ± 4 81 ± 3 96 ± 4 
T-β-MCA 0.2 10 ± 3 1.9 0.9945 4000 – 0.1221 71 ± 10 110 ± 3 80 ± 6 
T-UDCA 0.2 11 ± 1.5 4.1 0.9967 4000 – 0.1221 73 ± 3 78 ± 4 93 ± 3 
*1. Data are presented as the average ±% R.S.D of three levels of QC concentrations (20 nM, 200 nM and 2 µM), six samples per 
concentration. N.A.*2 Not applicable: LLOQs were determined as the lowest concentration in which these analytes were quantified with 
sufficient precision (CV of 15%) and accuracy (between 85% and 115%). 
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Table 4 Quantitative assessment of matrix effects for BAs. The analytical response in presence of matrix was expressed as a percentage 
of the analytical response in the absence of matrix. 
 
 Relative response (%) 
 
20 nM 200 nM 2 000 nM 
CA 108 ± 6 99 ± 14 114 ± 5 
CDCA 91 ± 3 110 ± 6 115 ± 1 
DCA 90 ± 15 114 ± 1 114 ± 3 
7-oxoDCA 87 ± 10 104 ± 10 110 ± 2 
HDCA 100 ± 10 111 ± 5 111 ± 1 
LCA 77 ± 9 105 ± 1 106 ± 3 
7-oxoLCA 87 ± 10 115 ± 7 114 ± 5 
α-MCA 103 ± 15 103 ± 8 109 ± 1 
β-MCA 95 ± 13 104 ± 10 115 ± 3 
ω-MCA 92 ± 13 99 ± 6 112 ± 2 
UDCA 97 ± 7 105 ± 9 113 ± 2 
G-CA 89 ± 15 102 ± 8 113 ± 2 
G-CDCA 92 ± 12 102 ± 7 114 ± 1 
G-DCA 96 ± 15 114 ± 2 111 ± 4 
G-LCA 107 ± 2 113 ± 2 115 ± 2 
G-7-oxo-LCA 112 ± 3 113 ± 1 111 ± 2 
G-UDCA 105 ± 4 120 ± 1 115 ± 3 
T-CA 98 ± 3 96 ± 6 115 ± 2 
T-CDCA 114 ± 6 107 ± 3 114 ± 2 
T-DCA 111 ± 10 113 ± 1 118 ± 1 
T-LCA 106 ± 7 114 ± 1 112 ± 3 
T-7-oxo-LCA 99 ± 2 112 ± 2 111 ± 2 
T-β-MCA 84 ± 12 99 ± 6 97 ± 4 
T-UDCA 98 ± 4 115 ± 4 115 ± 2 
Data is presented as the average ± CV (%). 
 5 
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Table 5. BA profiling in rat plasma followed by uninephrectomy 
Primary BAs 
1 week 
Sham 
1 Week 
UNX Fold increase 
1 Weeks 
Sham 
2 Weeks 
UNX Fold increase 
4 Weeks 
Sham 
4 Weeks 
UNX Fold increase 
α-MCA 381 ± 332 642 ± 326  1.7 616 ± 486 481 ± 391 0.8 256 ± 187 328 ± 2000 1.3 
β-MCA 357 ± 335 428 ± 166 1.2 346 ± 256 429 ± 384 1.2 252 ± 201 338 ± 235 1.3 
CDCA 483 ± 420 1052 ± 436 * 2.2 801 ± 576 794 ± 577 1 644 ± 602 380 ± 310 0.6 
CA 795 ± 653 1860 ± 1515 2.3 1037 ± 881 1192 ± 1094 1.1 884 ± 576 830 ± 669 0.9 
Total 2016 ± 202 3983 ± 632* 2 2800 ± 292 2896 ± 351 1 2035 ± 310 1878 ± 242 0.9 
Secondary BAs 
         LCA 14 ± 7 17 ± 9 1.3 9 ± 6 14 ± 4 1.6 5 ± 1 6 ± 2 1.2 
DCA 22 ± 15 46 ± 34 2.1 38 ± 27 58 ± 48 1.5 40 ± 25 55 ± 24 1.4 
UDCA 176 ± 161 300 ± 137 1.7 243 ± 162 230 ± 168 0.9 131 ± 62 160 ± 93 1.2 
HDCA 199 ± 119 214 ± 158 1.1 372 ± 371 398 ± 419 1.1 209 ± 247 213 ± 248 1 
7-oxoLCA 23 ± 25 38 ± 23 1.6 35 ± 30 55 ± 52 1.6 22 ± 16 23 ± 14 1.1 
7-oxoDCA 482 ± 590 479 ± 222 1 716 ± 779 645 ± 745 0.9 249 ± 254 323 ± 184 1.3 
ω-MCA 69 ± 36 111 ± 61 1.6 107 ± 79 163 ± 155 1.5 90 ± 64 121 ± 67 1.4 
Total 986 ± 169 1204 ± 170* 1.2 1519 ± 256 1563 ± 228 1.0 746 ± 94 901 ± 114 1.2 
Taurine-conjugated BAs 
         T-UDCA 3 ± 1 4 ± 1* 1.2 3 ± 1 5 ± 4* 1.9 2 ± 1 4 ± 3 1.5 
T-CDCA 52 ± 22 59 ± 16 1.1 33 ± 19 31 ± 13 0.9 25 ± 10 34 ± 21 1.3 
T-CA 150 ± 38 189 ± 79 1.3 134 ± 73 213 ± 85* 1.6 123 ± 60 190 ± 124 1.5 
T-DCA 6 ± 4 8 ± 6 1.3 7 ± 3 12 ± 9 1.8 7 ± 5 12 ± 9 1.8 
T-LCA ND 1 ± 0.7* 
 
ND 2 ± 4 
 
ND 1 ± 0.6* 4.5 
T-α-MCA 320 ± 100 300 ± 88 0.9 279 ± 99 348 ± 159 1.2 269 ± 92 286 ± 168 1.1 
T-β-MCA 56 ± 31 47 ± 7 0.8 48 ± 29 85 ± 64 1.8 62 ± 26 67 ± 48 1.1 
T-7oxo-LCA 3 ± 1 3 ± 1 1.3 2 ± 1 5 ± 3* 2 3 ± 1 3 ± 2 1.2 
Total 591 ± 112 612 ± 110 1 506 ± 98 700 ± 127 1.4 490 ± 94 597 ± 107 1.2 
Glycine-conjugated BAs         
 G-CA 29 ± 13 27 ± 15 0.9 51 ± 58 93 ± 95 1.8 79 ± 84 84 ± 76 1.1 
G-UDCA N.D. N.D.  N.D. N.D.  N.D. N.D. 
 G-CDCA 3 ± 1 3 ± 2 0.9 5 ± 2 8 ± 8 1.6 7 ± 6 7 ± 6 1 
G-DCA 0.4 ± 0.4 1 ± 0.9 1.2 1.5 ± 1.6 4 ± 6 2.9 3 ± 4 4 ± 3 1.2 
G-LCA N.D. N.D.  N.D. N.D.  N.D. N.D. 
 G-7oxo-LCA N.D. N.D.  N.D. N.D.  N.D. N.D. 
 Total 33 ± 14 31 ± 13 0.9 57 ± 24 106 ± 44 1.8 90 ± 38 95 ± 40 1.1 
 
The results are expressed in nM as mean ± standard deviation (n=8). N.D.: not detected. Underlined values represent below lower limit of quantification. Sham, sham-operated control rats; 
UNX, uninephrectomized rats. Statistics: * for p ≤ 0.05  
 5 
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